The abstract is read at the publisher; the summary is JClub's.
In older adults during cold and flu season, daily IDP supplementation (50 mg/day or 200 mg/day) is linked to faster reductions in cough and chest congestion severity and duration versus placebo.
- Why it matters: Upper respiratory infections are common and more burdensome in older adults, and prior IDP findings on vaccine antibody responses suggest a possible role in reducing symptom burden.
- What they did: A randomized, double-blind, placebo-controlled trial assigned 255 participants to placebo, 50 mg IDP/day, or 200 mg IDP/day for 16 weeks, with daily symptoms tracked using WURSS-24 and quality of life via SF-36.
- The result: Chest congestion and cough improved significantly faster in both IDP dose groups than placebo (area-under-the-curve comparisons with KW p 0.05), while SF-36 did not differ and adverse events potentially attributable to product use were infrequent and similar across arms.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.